Fan Site: Inspired, Not Endorsed, By Rakesh Jhunjhunwala

Top 12 High Conviction Stock Picks By Edelweiss (Jan 15)



Edelweiss has released a report of its high conviction stock picks with the potential for market beating returns




Edelweiss Top Picks are high conviction stocks which have the potential to generate market-beating returns over the next 12-18 months. Edelweiss Top Picks have delivered a CAGR return of 40% since inception as against Nifty CAGR return of 17%, translating into an outperformance of 23% (p.a). On an annualized basis, Top Picks have delivered a return of 66% per annum as against Nifty return of 35%. The Top Picks portfolio is suitable for investors looking to invest for the next 12-18 months.

Click here to download Edelweiss high conviction picks for Jan 2015
investments, Mid Cap, Multibagger, Portfolio, Top Picks    , ,

1 Comment
  1. Sumit's Gravatar Sumit
    January 5, 2015 at 10:06 pm | Permalink

    Edelweiss initiate coverage on Agro Tech Food. Any view on it?

    Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 480 other subscribers

RSS Stocks Talk Forum

  • Va Tech Wabag is a Buy for target price of ₹1700 (30% upside)
    Va Tech Wabag is ‘RIDING THE WAVE’. It is well-placed to serve the growing water security/conservation market. Rationale supported by a) Strong industry tailwinds, b) Improving profitability, c) Robust Order book, & d) Expanding offerings. TP ₹1700 (+30%) Download... Va Tech Wabag is a Buy for target price of ₹1700 (30% upside)
  • Zomato is not overvalued & is still a good buy: Manish Sonthalia
    Manish Sonthalia says there is no question of Zomato being overvalued though it is up 155% YoY. "The street will get surprised on numbers on FY26, FY27 & FY28. The Quick commerce of tripling of dark stores by FY26 is yet to play up”. Stay invested in stock [youtube https://www.youtube.com/watch?v=rVwYVaHV3oE]
  • Even if only US shifts 20-30%, Indian API revenues could triple or quadruple in 10 years
    Aditya Khemka says the US' Biosecure Act will benefit Pharma Cos like Piramal Pharma & Jubilant Pharmova which have mfg facilities in the US as they will be the first order beneficiary. Indian API exports are $4B while China's API exports are $40B. Even if only US shifts 20-30%, Indian API revenues could triple or […]
Disclaimer: This is a Fan Site in Rakesh Jhunjhunwala's name. Rakesh Jhunjhunwala is not associated with us and is in no way aware, accountable or responsible for what is stated here. Further, nothing here constiutes investment advice for you to act on. Also, we have a vested interest, and are extremely biased, in everything that we say. So Mind It!